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Abstract 
Renal Denervation for Resistant Hypertension 
Renal denervation as a treatment for hypertension ( HTN)  has been shown to be effective 
as a surgical procedure. Over the past ten years, an endovascular approach to replicate the 
results of surgical splanchnicectomy has been investigated to replace this surgical 
procedure with a less invasive procedure with lower morbidity. Several devices and 
procedures have been developed, including a non-invasive strategy. We review the 
improvement of HTN in clinical trials of these devices as well as the shortcomings of 
these studies. Thus far, these trials have been unable to prove that these renal denervation 
strategies are superior to medical therapy alone, but we look forward to further 
randomized, double blinded trials of current systems that can effectively achieve 
denervation to reduce the risk of HTN.  
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Abbreviations: 
 
AA – African-American 
 
BP – blood pressure 
 
DBP – diastolic blood pressure 
HTN – hypertension or hypertensive 
LVH –left ventricular hypertrophy 
NHANES - National Health and Nutrition Examination Survey 
RDN – renal denervation 
RF – radiofrequency 
SBP – systolic blood pressure 
SNS – sympathetic nervous system 
SSAHT -standardized stepped-care antihypertensive treatment  
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Nearly one third of Americans, approximately 80 million, have hypertension (HTN) and 
only 55% of those people have their blood pressure ( BP) controlled.
1
 HTN is implicated 
in coronary heart disease, congestive heart failure and stroke. National Health and 
Nutrition Examination Survey (NHANES) data show that 11.5% of Americans with HTN 
have resistant HTN, defined as BP greater than 140/90 mm Hg despite using three or 
more anti-HTN medications.
2
  
 
The sympathetic nervous system (SNS) and parasympathetic nervous systems control the 
autonomic systems throughout the human body in a competitive yet complimentary 
manner, each playing the yin to the other’s yang. The SNS responds whenever a rapid 
response is required, the “fight or flight” response. In the cardiovascular system, the SNS 
increases the heart rate and dilates the coronary arteries. Peripherally, it increases BP, 
which has made it a target for therapy of HTN for nearly eighty years. Microneurography 
has been used to measure the efferent activation of peripheral sympathetic nerves and is 
described as number of activations per minute. In a study of the SNS activity in ninety 
untreated patients, those with normal office BP had the lowest frequency of nerve 
activations. Using normotensives as the reference, pre-HTN, those with any stages of 
HTN, including those with left ventricular hypertrophy (LVH), had significantly 
increased frequency of SNS activity as measured by microneurography.
3
  
 
The renal SNS consists of efferent and afferent pathways which both play important roles 
in HTN. The efferent pathway delivers sympathetic signals to the kidney from the central 
nervous system. Norepinephrine acts as the neurotransmitter stimulating β1-
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adrenoreceptors on the juxtaglomerular apparatus to increase renin secretion. α1B 
adrenoreceptors on the renal tubular epithelial cells increase sodium reabsorption. 
Stimulation of α1A adrenoreceptors constricts the parenchymal renal vasculature, 
decreasing renal blood flow. Sensory afferent fibers are located in the wall of the renal 
pelvis. These fibers signal the contralateral kidney, promoting natriuresis and diuresis, 
coordinating the function of each kidney. Afferent pathways from the kidneys relay 
signals from the renal pelvis back to the central nervous system. In response the central 
sympathetic efferent nerves cause increased heart rate and BP. Renal denervation systems 
cannot discriminate between the efferent and afferent fibers. Fortunately, both are 
involved in the physiology of HTN and simultaneously ablated. 
 
The anatomy of the kidney’s sympathetic nerves impacts the accessibility to a catheter 
based therapy for renal denervation (RDN); the location of the nerve relative to the vessel 
and the depth at which those nerves are located within the wall may impact the efficacy 
of denervation. Although some studies have suggested that the nerve fibers are relatively 
deep,
4
 Atherton examined post mortem specimens and reported that 50% of renal nerves 
are located within 1 mm of the lumen and 90% less than 2 mm deep.
5
 Investigators 
performed autopsies on 25 humans, identifying ten thousand nerves along the renal 
arteries. Less than 10% of these nerves were less than 1 mm deep. But 80% of the nerves 
are found from 1mm to 6 mm from the vessel lumen.
6
 The nerves were evenly distributed 
around the axis of the vessel. However, the depth of the nerves in the distal renal artery 
and branches was significantly more shallow than in the middle and proximal segments 
of the vessel. (Figure 1 and 2) 
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Renal denervation procedures 
In 1938, thoracolumbar splanchnicectomy was first introduced for the treatment of HTN . 
In 1953, Smithwick and Thompson reported their experience with 1,253 patients treated 
with splanchnicectomy, compared to 467 patients in the control group who were treated 
with medical therapy. The surgical and medically managed patients with essential HTN 
were divided into four groups based on the severity of their HTN. For each group, the 
survival at five years was superior in the surgical group as compared to the medical 
group. 
7
 When successful, this operation was a potent treatment for HTN; 81 % of 
patients who underwent splanchnicectomy achieved significant reductions in systolic and 
diastolic BP ( SBP,  DBP) with slightly over 20 % of patients achieved a normal BP 5-12 
years after the operation and 26% of patients had an 80 mm Hg reduction in SBP and 25 
mm Hg fall in DBP, and 35% had a 40 mm Hg reduction of SBP and 15 mm Hg 
reduction in DBP 5-12 years after surgery.
8
 However, there was significant morbidity 
associated with the surgery, and it was abandoned as pharmacologic therapies improved.
9
 
 
Most modern RDN procedures are performed percutaneously with catheter based 
systems. The approach to the renal artery is commonly from a femoral approach, but the 
radial/brachial artery access is preferred by many. Each renal artery is treated 
sequentially. Radiofrequency (RF) energy or therapeutic ultrasound is applied 
“endoluminally” to ablate the renal nerves. The Symplicity RDN system (Medtronic, 
Minneapolis, MN), has the most clinical data. (Figure 3) This 6 Fr guide compatible 
catheter has a single electrode on the distal tip of the catheter. It is not delivered over a 
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guidewire, but has a steerable tip. The generator measures impedance as a surrogate for 
vessel wall contact. The catheter is delivered to the distal segment of the renal artery, a 
series of applications of RF energy are delivered in a helical pattern back to the proximal 
portion. (Figure 4) 
 
The EnligHTN system (St. Jude Medical, St. Paul, MN) is delivered with an 8 Fr guiding 
catheter. A self expanding basket consisting of four arms is opened in the renal artery to 
achieve vessel wall contact without occluding renal blood flow (Figure 5). Each arm is 
equipped with an electrode to deliver the RF energy. All four electrodes simultaneously 
deliver energy. The Vessix V2 system (Boston Scientific, Natick, MA) (Figure 6), and 
One Shot RDN device (Covidien, Campbell, CA) (Figure 7) have RF energy emitting 
electrodes evenly distributed on a balloon that ensures contact with the vessel wall, 
although it occludes flow during the treatment. The Radiance Paradise catheter (Recor 
Medical, Ronkonkoma, NY) has a centering, occlusive balloon as well, delivering 
therapeutic ultrasound energy from a transducer within the balloon heating the renal 
arterial wall so that thermal energy ablates the nerves.(Figure 8) The catheter is cooled 
with circulating saline to minimize thermal damage to the endothelium and the first 1 mm 
of the vessel.  
 
In addition to RF or ultrasound energy based RDN systems, chemical denervation is 
being explored as well. Local injection of the chemotherapeutic agent vincristine into the 
renal artery media to achieve renal denervation has been explored. 
10, 11
  The device used 
to perform this injection consisted of a balloon in balloon device. The outer balloon has 
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evenly distributed holes to infuse the vincristine; the inner balloon is inflated to anchor 
the drug delivery balloon in place. The Peregrine infusion catheter (Ablative Solutions, 
Kalamazoo MI) is an endovascular device with three small needles at the distal tip of the 
device.(Figure 9) Once extended, these needles, arrayed evenly around the axis of the 
catheter, are reflected back toward the proximal end of the catheter.
12
  
 
A novel non-invasive system (Kona Medical, Bellevue, WA) for RDN using ultrasound 
energy delivered externally has shown feasibility and safety in humans.
13
 In the initial 
trial subjects, an endovascular targeting catheter was positioned in the renal artery to 
guide the ultrasound. However, subsequently, subjects have been successfully treated 
using only external, non-invasive transabdominal ultrasound. The focused ultrasound 
beam is delivered from an external source to heat the adventitia of the renal arteries to 
ablate nerve tissue.  
 
Results of efficacy trials 
The initial results of the open label Symplicity HTN 1 trial were widely greeted as a 
potential breakthrough technology; 50 patients with treatment resistant HTN were 
enrolled, and five were excluded for renal anatomy that was not amenable to the 
procedure. The mean reduction in office BP at 6 months was 22 mm Hg and 11 mm Hg  
for SBP and DBP, respectively. The reduction in BP was seen as early as one month after 
the procedure.
14
 (Figure 10) The follow up study, HTN 2, was another multicenter, open 
label design trial.
15
 But in contradistinction to the initial HTN1 trial, patients with 
resistant HTN were compared. They successfully randomized 106 patients; at 6 months, 
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the RDN patients had a 32 mm Hg drop in their systolic blood pressure compared to 
baseline (p < 0.001) while those who continued medical therapy alone saw an increase in 
their SBP of 7 mm Hg (p < 0.026). After the 6-month endpoint was reached, patients in 
the control arm were allowed to crossover to the RDN arm. The patients who were 
initially randomized to RDN maintained their BP 28 mm Hg lower than their baseline 
measurement. For the 35 crossover patients, the 6 month systolic office SBP measured 24 
mm Hg lower than their baseline at trial enrollment.
16
 
 
The pivotal trial for the Symplicity system was the multi-center, randomized, double 
blinded sham-controlled study, HTN 3. The crucial difference between this trial and its 
predecessors was the use of the invasive renal angiogram as a sham procedure for the 
patients who were blinded throughout the follow up period.
17
 All patients undergoing the 
procedure were required to undergo angiography. Once their renal anatomy was 
confirmed to be appropriate for RDN they were randomized while still on the table. All 
patients were blinded to their treatment allocation. All patients were to be maintained on 
their baseline medical regimen. At the six-month follow up, there was no difference for 
lower SBP in the subjects in the RDN arm (14.1 + 23.9 mm Hg) versus the control arm 
(11.7 + 25.9 mm Hg, P = 0.26). 
 
There was no control group in the HTN1 trial, but HTN2, though unblinded, was a 
randomized comparison between RDN and medical therapy. There was no appreciable 
improvement in blood pressure among the control group.
15
 At 6 months the office based 
SBP changed only 1 mm Hg, and the DBP did not change at all. This lack of 
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improvement is atypical for HTN trials, participation alone benefits subjects in control 
arms as close follow up improves medication adherence as well as life style 
modifications. The absence of a positive effect in the control arm highlights a possible 
reverse placebo effect. Subjects knew they did not receive the RDN procedure, and their 
BP remained flat. Perhaps knowing that they could potentially crossover to the active 
treatment tempered their enthusiasm for their medical regimen as they anticipated a 
future RDN procedure. In fact, there was a negative incentive as the subjects wanted to 
remain eligible for the active treatment arm of the trial.  
 
Did the Symplicity HTN 3 trial demonstrate the importance of sham-controlled double 
blinded studies, and the potential for a profound placebo effect? Did the first two studies 
overestimate the benefit of RDN? Patients enrolled in the study were required to be on 
the maximal tolerated dosage of three medications including a diuretic and underwent a 
two week observation period to document their compliance with medications. But nearly 
40% of the subjects underwent at least one medication change between enrollment and 
the 6 month endpoint. If medication classes were changed as well as dosages of the 
medications, perhaps the patients were not receiving a maximally tolerated regimen? 
18
 
 
In a multivariate analysis of subgroups in the Symplicity HTN 3 trial, a baseline office 
SBP > 180 mm Hg and the prescription of an aldosterone inhibitor predicted a greater 
reduction in office SBP at 6 months than was seen in the overall group.
18
 Aldosterone 
inhibitor use was also associated with a greater response for 24 hour ambulatory BP 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
reduction. The use of vasodilators at baseline were negative predictors of BP lowering at 
6 months. 
 
In Symplicity HTN 3, 26% of the population was African American (AA), which was not 
true for HTN 1 and 2, which were performed outside the United States. AAs experienced 
no significant treatment difference in office SBP at six months between the RDN and 
sham controlled groups, whereas non-AAs had a statistically significant 6.6 mm Hg (CI -
11.8 to – 1.4, p = 0.01) difference in response between sham and RDN groups (-8.6 vs -
15.2 mm Hg). However, the P value for the difference in efficacy of RDN between the 
AAs and non-AAs was not statistically significant (p = 0.09) and home SBP and 24 hour 
ambulatory SBP were not different between AAs and non-AAs. 
 
Subjects with longer renal arteries could potentially receive more ablation attempts than 
those with shorter renal arteries. Subjects who received more ablation attempts in the 
RDN group did have a greater reduction in office and ambulatory 24 hour BP at six 
months as compared to those with fewer attempts.
18
 Delivery of radiofrequency energy in 
all four quadrants of the renal artery was also associated with a greater response in office 
BP. This dose response for RDN argues for an objective benefit for sympathetic 
denervation of the renal arteries for the treatment of HTN.  
 
Perhaps the failure of the Symplicity HTN 3 trial to demonstrate superiority was related 
to incomplete ablation specifically related to the delivery device. Most investigators in 
the Symplicity HTN 3 trial were not experienced in RDN and half of the investigators 
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performed only two RDN procedures and 31% performed only one procedure in the trial. 
Although the device generator provides feedback confirming catheter contact with the 
vessel wall, there was no measurement of effectiveness in achieving RDN or reduction in 
sympathetic tone. If more patients had received more than 12 denervation lesions, as 
compared to the minimum of 8 lesions prescribed by the trial, perhaps a greater impact on 
SBP would have been achieved. 
 
The Global Symplicity Registry was a multi-center, open label registry of RDN 
procedures used to describe “real world” efficacy and safety. This registry compared the 
effect of operator experience on safety and efficacy of RDN;  59% of the operators had 
performed more than 15 RDN procedures prior to the launch of the registry. The 
indication for RDN was at the discretion of the operator. Of the 998 patients in the 
registry, 323 procedures were performed for severe HTN. Indications for the remainder 
of the patients was not well described, but appear to include LVH, atrial fibrillation and 
sleep apnea. Among these HTN patients, there was 20.3 + 22.8 mm Hg drop in office and 
an 8.9 + 16.9 mm Hg drop in 24 hour SBP (p < 0.001) as compared to their baseline 
reading. This was a greater drop as compared to the overall group (11.6 + 25.3, 6.6 + 18.0 
mm Hg), although the drop in SBP at six months from the baseline measurement was 
statistically better for the overall group as well (p < 0.001). 
 
There was heterogeneity of medical regimens among patients in the Symplicity trial, and 
this may have affected the outcomes of the trial. Patients enrolled in the Symplicity trial 
were meant to have been on a maximally tolerated drug regimen for HTN. Yet 39 % of 
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patients underwent changes in their medical regimen, both dosage and change in drug 
class, during the 6 weeks of follow up. In an effort to reduce variation in the trial, patients 
with HTN resistant to a standardized three drug regimen were enrolled in the trial; 
subjects were on indapamide 1.5 mg, ramipril 10 mg and amlodipine 10 mg daily.   The 
DenerHTN trial used the Symplicity system for RDN compared to patients on a 
standardized medical regimen in a randomized multi-center trial with blinded 
investigators determining the follow up endpoints. 
19
 The operators and subjects were not 
blinded. Those subjects with SBP > 140 mm Hg or a DBP > 90 mm Hg were enrolled. 
The experimental arm underwent RDN using the Symplicity system combined with 
standardized stepped-care anti-HTN treatment (SSAHT) increase in medical regimen, 
adding spironolactone 25 mg daily, bisoprolol 10 mg daily, prazosin 5 mg daily and 
rilmenidine 1 mg daily in a programmatic manner, stepwise until SBP was controlled. 
The control arm received SSAHT alone. The primary endpoint was the mean reduction in 
ambulatory SBP at 6 months. The mean difference between the two treatment arms was 
5.9 mm (95% CI 0.5 to 11.3, p = 0.0329) Hg lower in the RDN arm compared to 
SSAHT.(Figure 11) 
 
Using the Peregrine system described above, chemical renal artery denervation has been 
reported in a small pilot study by Fischell et al.  This was a single center, single arm 
study injecting microdoses of ethanol to the perivascular space in 18 HTN patients. There 
were no procedural complications of dissection, perforation or spasm noted during the 
procedure or on the follow up angiogram at six months. At the six month follow up there 
was a 24 + 22 mm Hg reduction in office SBP and a 12 + 9 mm Hg reduction in DBP.  
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Summary 
RDN as a treatment for HTN has been shown to be effective as a surgical procedure, 
splanchnicectomy. Over the past 10 years, investigators sought to develop an 
endovascular approach to replicate the results of surgical splanchnicectomy with a less 
invasive procedure with lower morbidity.(Figure 12) Several procedures have been 
developed, including a non-invasive strategy. But to date, investigators have been unable 
to prove that these RDN strategies are superior to medical therapy alone which is vastly 
superior to the drugs available when surgical splanchnicectomy was studied. 
We look forward to further randomized, double blinded trials of renal denervation to 
determine if the current systems can effectively achieve denervation to reduce the risk  
and complications of   HTN. 
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Figure Legend 
 
Figure 1) A post mortem analysis of the anatomic distribution of sympathetic nerves 
in the renal arteries. Over 90% of the renal nerves are located within the first 2 mm of 
the vessel wall. Fewer nerves were found deeper in the vessel wall. There was no 
difference in the distribution of these nerves as arrayed around the vessel wall. 
(Sakakura et al.)  
 
Figure 2) The distribution of the mean number of nerves in relationship to the 
position along the length of the vessel. (Sakakura et al) 
 
Figure 3) Symplicity renal denervation catheter (Medtronic, Minneaspolis, MN) 
which consists of a flexible tip seen in the inset box. The handle is used to control the 
degree of angulation. 
 
Figure 4)  Schematic drawing representing the helical pattern of ablative lesions in 
the renal artery, seen here in an end on view in panel A. In panel B the renal artery is 
displayed after a longitudinal cut and opening the artery to display this spiral pattern 
of denervation lesions. 
 
Figure 5) EnligHTN catheter (St. Jude Medical, St. Paul, MN) has four arms that can 
be expanded to touch the vessel wall by turning the handle. An electrode on each arm 
can deliver RF energy simultaneously for renal denervation.  
 
Figure 6) Vessix V2 system (Boston Scientific, Natick, MA) uses a balloon to ensure 
the RF delivery electrodes are apposed to the vessel wall. Energy is applied 
simultaneously along the length and circumference of the balloon. 
 
Figure 7) One Shot denervation system (Covidian, Campbell, CA) has multiple RF 
electrodes on the balloon which centers the catheter and ensures vessel wall 
apposition to assure renal nerve ablation. 
 
Figure 8)  The Radiance system (Recor Medical, Ronkonkoma, NY) consists of a 
therapeutic ultrasound transducer within centering balloon that is irrigated with cool 
saline to  reduce thermal injury to the endothelium in the upper panel. The lower 
panel demonstrates the ultrasound delivery in the red ring, while the endothelium is 
cooled by the balloon   (blue ring). 
 
 
Figure 9) The Peregrine infusion system (Ablative Solutions, Palo Alto, CA), white 
arrows highlight the needles that extend from the catheter once it is correctly 
positioned for the injection of the ablative solution. 
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Figure 10)  The results from the HTN 1 trial demonstrating a reduction from baseline 
measurements of in office measurement of systolic (red) and diastolic (blue) blood 
pressure over twelve months. 
 
Figure 11) Changes in blood pressure comparing patients treated with standardized 
stepped-care antihypertensive treatment (SSHAT) in red as compared to patients who 
were treated with SSHAT and renal denervation using the St. Jude system. Systolic 
(Sys), ambulatory blood pressure (ABP), diastolic (Dias), systolic blood pressure 
(SBP), diastolic blood pressure (DBP), asterisks denote p value < 0.05. 
 
 
Figure 12) Panel A demonstrates the baseline angiogram of the right renal artery. 
Panels B, C and D demonstrate the Symplicity catheter applying a series of 
radiofrequency ablations to the renal nerves. In panel D, “notching’ is noted on the 
inferior aspect of the vessel, a benign finding frequently seen after renal denervation 
therapy. 
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Figure 12 
